Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia.

Autor: van Weelderen RE; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Emma Children's Hospital, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Harrison CJ; Leukemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle-upon-Tyne, United Kingdom., Klein K; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Emma Children's Hospital, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Department of Pediatrics, Wilhelmina Children's Hospital/University Medical Center Utrecht, Utrecht, The Netherlands., Jiang Y; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Abrahamsson J; Department of Pediatrics, Institute of Clinical Sciences, Salgrenska University Hospital, Gothenburg, Sweden., Alonzo T; Division of Biostatistics, University of Southern California, Los Angeles, CA., Aplenc R; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA., Arad-Cohen N; Department of Pediatric Hematology-Oncology, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel., Bart-Delabesse E; Institut Universitaire du Cancer Toulouse-Oncopole, Laboratoire d'Hématologie secteur Génétique des Hémopathies, Toulouse, France., Buldini B; Division of Pediatric Hematology, Oncology, and Stem Cell Transplant, Department of Maternal and Child Health, Padua University, Padua, Italy., De Moerloose B; Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium., Dworzak MN; Department of Pediatrics, St. Anna Children's Hospital, Medical University of Vienna & St. Anna Children's Cancer Research Institute, Vienna, Austria., Elitzur S; Department of Pediatric Hematology and Oncology, Schneider Children's Medical Center & Tel Aviv University, Tel Aviv, Israel., Fernández Navarro JM; Department of Pediatric Oncohematology, Hospital Universitari i Politècnic la Fe, Valencia, Spain., Gamis A; Department of Hematology and Oncology, Children's Mercy Hospital, Kansas City, MO., Gerbing RB; Department of Statistics, Children's Oncology Group, Monrovia, CA., Goemans BF; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., de Groot-Kruseman HA; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; DCOG, Dutch Childhood Oncology Group, Utrecht, The Netherlands., Guest E; Department of Hematology and Oncology, Children's Mercy Hospital, Kansas City, MO., Ha SY; Department of Pediatrics & Adolescent Medicine, Hong Kong Children's Hospital, Kowloon Bay, Hong Kong., Hasle H; Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark., Kelaidi C; Department of Pediatric Hematology and Oncology, Aghia Sophia Children's Hospital, Athens, Greece., Lapillonne H; Department of Pediatric Hematology and Oncology, Hôpital Armand Trousseau, Paris, France., Leverger G; Department of Pediatric Hematology and Oncology, Hôpital Armand Trousseau, Paris, France., Locatelli F; Department of Pediatric Hematology and Oncology and Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome, Italy., Miyamura T; Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan., Norén-Nyström U; Department of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden., Polychronopoulou S; Department of Pediatric Hematology and Oncology, Aghia Sophia Children's Hospital, Athens, Greece., Rasche M; Department of Pediatric Hematology and Oncology, University Hospital Essen, Essen, Germany., Rubnitz JE; Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN., Stary J; Department of Pediatric Hematology and Oncology, University Hospital Motol and Second Faculty of Medicine, Charles University, Prague, Czech Republic., Tierens A; Department of Pathobiology and Laboratory Medicine, University Health Network, Toronto General Hospital, Toronto, ON, Canada., Tomizawa D; Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan., Zwaan CM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Pediatric Oncology, Erasmus Medical Center Sophia Children's Hospital, Rotterdam, The Netherlands., Kaspers GJL; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Emma Children's Hospital, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Publikováno v: Blood advances [Blood Adv] 2024 Jun 25; Vol. 8 (12), pp. 3200-3213.

Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A -Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group.

Autor: van Weelderen RE; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Klein K; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.; Wilhelmina Children's Hospital/University Medical Center Utrecht, Utrecht, the Netherlands., Harrison CJ; Leukemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle-upon-Tyne, United Kingdom., Jiang Y; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Abrahamsson J; Department of Pediatrics, Institute of Clinical Sciences, Salgrenska University Hospital, Gothenburg, Sweden., Arad-Cohen N; Pediatric Hemato-Oncology Department, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel., Bart-Delabesse E; IUC Toulouse-Oncopole, Laboratoire d'Hématologie secteur Génétique des Hémopathies, Toulouse, France., Buldini B; Pediatric Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, Padua University, Padua, Italy., De Moerloose B; Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium., Dworzak MN; St. Anna Children's Hospital, Department of Pediatrics, Medical University of Vienna, and St Anna Children's Cancer Research Institute, Vienna, Austria., Elitzur S; Department of Pediatric Hematology and Oncology, Schneider Children's Medical Center and Tel Aviv University, Tel Aviv, Israel., Fernández Navarro JM; Pediatric Oncohematology Unit, Hospital Universitari i Politècnic la Fe, Valencia, Spain., Gerbing RB; Department of Statistics, The Children's Oncology Group, Monrovia, California., Goemans BF; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., de Groot-Kruseman HA; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; DCOG, Dutch Childhood Oncology Group, Utrecht, the Netherlands., Guest E; Children's Mercy Kansas City, Kansas City, MO., Ha SY; Department of Pediatrics & Adolescent Medicine, Hong Kong Children's Hospital, Kowloon, Hong Kong., Hasle H; Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark., Kelaidi C; Department of Pediatric Hematology and Oncology, Aghia Sophia Children's Hospital, Athens, Greece., Lapillonne H; Pediatric Hematology and Oncology Department, Hôpital Armand Trousseau, Paris, France., Leverger G; Pediatric Hematology and Oncology Department, Hôpital Armand Trousseau, Paris, France., Locatelli F; Department of Pediatric Hematology and Oncology and Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome, Italy., Masetti R; Pediatric Oncology and Hematology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Bologna, Italy., Miyamura T; Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan., Norén-Nyström U; Department of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden., Polychronopoulou S; Department of Pediatric Hematology and Oncology, Aghia Sophia Children's Hospital, Athens, Greece., Rasche M; Department of Pediatric Hematology and Oncology, University Hospital Essen, Essen, Germany., Rubnitz JE; Department of Oncology, St Jude Children's Research Hospital, Memphis, TN., Stary J; Department of Pediatric Hematology and Oncology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic., Tierens A; Department of Pathobiology and Laboratory Medicine, University Health Network, Toronto General Hospital, Toronto, ON, Canada., Tomizawa D; Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan., Zwaan CM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands., Kaspers GJL; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Jun 01; Vol. 41 (16), pp. 2963-2974. Date of Electronic Publication: 2023 Mar 30.

Effect of Antibacterial Prophylaxis on Febrile Neutropenic Episodes and Bacterial Bloodstream Infections in Dutch Pediatric Patients with Acute Myeloid Leukemia: A Two-Center Retrospective Study.

Autor: Van Weelderen RE; Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, 1105 AZ Amsterdam, The Netherlands.; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands., Klein K; Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, 1105 AZ Amsterdam, The Netherlands.; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.; Wilhelmina Children's Hospital, University Medical Center Utrecht, 3584 EA/CX Utrecht, The Netherlands., Goemans BF; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands., Tissing WJE; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.; Department of Pediatric Oncology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands., Wolfs TFW; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.; Wilhelmina Children's Hospital, University Medical Center Utrecht, 3584 EA/CX Utrecht, The Netherlands., Kaspers GJL; Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, 1105 AZ Amsterdam, The Netherlands.; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

Publikováno v: Cancers [Cancers (Basel)] 2022 Jun 28; Vol. 14 (13). Date of Electronic Publication: 2022 Jun 28.